Genflow Biosciences Plc CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s latest progress in its dog longevity trial for GF-1004. The company has achieved a key safety milestone, with no adverse events reported to date. Leire emphasised that since GF-1004 is not treating a disease but intended to extend lifespan, a strong safety profile was critical. “Absolutely no side effect, absolutely no adverse event,” he said, noting that the drug is also easy for vets to administer. While safety and feasibility have now been confirmed, efficacy remains the next hurdle. Leire explained that biological age — not just chronological age — will be measured, using Steve Horvath’s DNA methylation test to assess changes over time. Additional endpoints include muscle mass (sarcopenia), mitochondrial function, coat quality, and telomere length. He also noted that positive results could support licensing deals with animal health companies, providing a non-dilutive financing route at a time when biotech fundraising is challenging. “The impact will be extremely important in terms of finance for the company,” he said. Importantly, dogs share similar biological ageing pathways with humans, offering greater translational value than traditional mouse models. For more videos from Proactive, don’t forget to like this video, subscribe to our channel, and enable notifications so you never miss an update. #GenflowBiosciences #DrEricLeire #DogLongevity #BiotechNews #AntiAgingResearch #GF1004 #VeterinaryMedicine #DNAAgeTesting #Telomere #MitochondriaHealth #AnimalHealth #BiotechInvesting #ProactiveInvestors